diazepam

Libervant provided tentative approval from the FDA for the acute treatment of intermittent, stereotypic episodes of frequent seizure activityLibervant U.S. Market Access currently subject to the expiration of Valtoco® orphan drug market…

WARREN, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve…

Prescription Drug User Fee Act (PDUFA) Target Goal Date set for December 23, 2021If approved by the FDA for U.S. market access, Libervant would be the first orally delivered diazepam product for the management of seizure clusters…